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e106Introduction: Diabetes-induced sexual dysfunction is associated with an increase in oxidative stress. Scavengers
of reactive oxygen species (ROS) have been shown to reduce oxidative stress and aid in the management of sexual
dysfunction in diabetes.
Aim: The aim of the study was to test the hypothesis that antioxidant, which scavenge ROS and reduce for-
mation of advanced glycation end products (AGEs), can potentiate efﬁcacy of phosphodiesterase type 5 inhibitors
in diabetes-induced sexual dysfunction that is associated with oxidative stress.
Materials and Methods: Effect of phloroglucinol and sildenaﬁl on serum glucose level, sexual function, penile
smooth muscle : collagen ratio, and phenylephrine precontracted corpus cavernosum smooth muscle (CCSM)
was studied. The ability of phloroglucinol to reduce the formation of AGEs and its ability to scavenge 2,2-
diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) was also evaluated.
Main Outcome Measures: Antioxidant potential of phloroglucinol was studied in addition to its effect on
diabetes-induced sexual dysfunction in presence and absence of sildenaﬁl.
Results: Phloroglucinol (50 mg/kg, p.o.) signiﬁcantly decreased serum glucose level and increased sexual
function in streptozotocin-induced diabetic rats when compared with diabetic control rats. Sildenaﬁl (5 mg/kg,
p.o.) had no effect on glycemia but signiﬁcantly increased sexual function of diabetic rats. Coadministration
of phloroglucinol increased the efﬁcacy of sildenaﬁl by improving sexual function. Treatment of diabetic rats
with phloroglucinol þ sildenaﬁl maintained smooth muscle : collagen levels similar to that of normal rat penile
tissue. Phloroglucinol decreased formation of AGEs and signiﬁcantly scavenged DPPH radical activity in vitro.
Sildenaﬁl relaxed isolated CCSM of normal rat and diabetic rat signiﬁcantly, but phloroglucinol did not
show any signiﬁcant effect. Phloroglucinol also inhibited human CYP3A4 enzyme activity in vitro.
Conclusion: Phloroglucinol coadministration increases efﬁcacy of sildenaﬁl in diabetes-induced sexual
dysfunction. However, further studies are required to ascertain the beneﬁts of phloroglucinol owing to its un-
desirable CYP3A4 inhibition activity.
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Diabetes mellitus is a metabolic disorder that is characterized by
increased blood sugar levels (hyperglycemia). India is home to
largest number of patients with diabetes in the world, and the
number is expected to reach 87 million by 2030.1 Type 1 diabetes
is characterized by lack of insulin secretion from pancreas.2 Dia-
betic complications include nephropathy, neuropathy, retinop-
athy, cardiovascular disease, and sexual dysfunction.3,4 SexualSex Med 2016;4:e106ee114
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can lead to loss of self-esteem.6
Oxidative stress associated with hyperglycemia damages the
penile smooth muscle and nerves that leads to sexual dysfunc-
tion.7,8 Though, phosphodiesterase inhibitors such as sildenaﬁl is
preferred medicine for managing erectile dysfunction (ED), a
male sexual dysfunction in diabetics, but it is reported not to be
100% efﬁcacious.9,10 Co-treatment of an antioxidant and sil-
denaﬁl has been reported to increase efﬁcacy of sildenaﬁl.7,11
We evaluated the effect of co-treatment of phloroglucinol, an
antioxidant and sildenaﬁl on sexual function of streptozotocin-
induced type 1 diabetic rats and compared it with the effect of
phloroglucinol and sildenaﬁl treatment under same physiological
condition.7,11,12 Effect of sildenaﬁl and phloroglucinol on phen-
ylephrine precontracted isolated rat corpus cavernosum smooth
muscles (CCSMs) was studied to evaluate their erectogenic po-
tential in normal rats.11 Phloroglucinol (1,3,5-trihydroxybenzene),
a polyphenol, is the monomeric building unit of phlorotannins,
phenolic compounds known only from brown algae (Phaeophy-
ceae).13 Polyphenols are known to reduce oxidative stress by
scavenging reactive oxygen species, chelating iron, and modulating
various enzymes.14 Increase in formation and accumulation of
AGEs in corpus cavernosum in diabetes was linked to ED.15
Therefore, we studied the effect of phloroglucinol on formation
of AGEs in vitro.16 Antioxidant potential of phloroglucinol was
evaluated by studying its effect on scavenging of DPPH and nitric
oxide (NO).17 Effect of phloroglucinol was studied on activity of
cytochrome P450 3A4 (CYP3A4), which metabolizes sildenaﬁl to
ﬁnd out possible pholoroglucinolesildenaﬁl interaction.18MATERIALS AND METHODS
Materials
Phloroglucinol and streptozotocin (STZ) were purchased from
Sigma-Aldrich (St Louis, MO, USA), whereas glucose estimation
kit was procured from Autospan (Surat, India). Human CYP3A4
substrate Benzyloxy-4-(triﬂuoromethyl) coumarin (BFC) was
collected from ChemBridge Corporation (San Diego, CA, USA),
whereas enzyme and BFC metabolite: 7-Hydroxy-4-(tri-
ﬂuoromethyl) coumarin (HFC) was from Corning Inc (Fremont,
CA, USA). Other reagent and chemicals procured were of
analytical grade.Animals
Three-month-old adult male and female Wistar rats weighing
about 175e225 g were used in the study. Thirty male rats and
equal number of female rats were used for the study. The use of
animals in these experiments was approved by Institutional
Animal Ethical Committee of Al-Ameen College of Pharmacy.
Experiments on rats were conducted in accordance with the
Committee for the Purpose of Control and Supervision of Experi-
ments on Animals guidelines. Rats were maintained under
controlled temperature at 25 ± 2C and relative humidity ofSex Med 2016;4:e106ee11445e55% with an alternating 12 h light/dark cycle (light ON
6:00e18:00 h). The animals were reared and maintained with
free access to food and water throughout the day.Induction of Type 1 Diabetes and Drug Treatment
Streptozotocin was dissolved in ice-cold 0.1 M sodium citrate
buffer just prior to use and injected intraperitoneally to male rats at a
dose of 55 mg/kg.7,11 Three days after administration of STZ,
fasting serum glucose level of overnight-fasted rats was analyzed as
per procedure mentioned in glucose estimation kit (Autospan, In-
dia) to conﬁrm induction of diabetes.11 This day was considered as
day 0, following which drug treatment was started.
Phloroglucinol was dissolved in distilled water and adminis-
tered daily to rats orally using per oral tube. The test solutions
were freshly prepared every day before dosing the animals.
Diabetic rats were administered with phloroglucinol for 4 weeks
post-induction of diabetes. Male rats were divided into ﬁve
groups as follows, each group containing six animals.
Group 1: Negative control, normal rats (water 4 mL/kg, p.o.)
Group 2: Positive control, diabetic rats (vehicle 4 mL/kg, p.o.
for 4 weeks)
Group 3: Diabetic rats administered with phloroglucinol (50
mg/kg, p.o. for 4 weeks)
Group 4: Diabetic rats administered with sildenaﬁl (5 mg/kg,
p.o. for 4 weeks)
Group 5: Diabetic rats administered with phloroglucinol (50
mg/kg, p.o.) þ sildenaﬁl (5 mg/kg, p.o.) for 4 weeks
Though study started with six animals in each group, few
animals were excluded from statistical calculation due to devel-
opment of sexual dysfunction and inability of individual treat-
ment to elevate sexual function in all animals.Sexual Behavior Study of Rats
Before induction of diabetes, all the male rats were trained
thrice for sexual activity in presence of ovariectomized estrous
female rats in an observation chamber on different days. The
male rats that did not perform intromission (vaginal penetration)
within 10 minutes of introduction of female rats were removed
from the study and those rats were replaced by sexually
active male rats. Female rats were treated with diethylstilbestrol
(1 mg/kg, p.o., administered 48 hours prior to sexual behavior
study) and progesterone (5 mg/kg, s.c., administered 4 hours
prior to the sexual behavior study) to induce artiﬁcial estrous
phase. Female rats that did not exhibit lordosis posture were not
paired with male rats for sexual behavior study.19,20
Sexual behavior study was performed in evening and night on
day 0 and 28. The study was performed as per published liter-
ature. Brieﬂy, after male rat accustoms to observation chamber
(5e10 minutes), a female rat was introduced and following
sexual behavior parameters were observed.19,20
e108 Goswami et alMount latency (ML): time from the introduction of female
into the cage of the male up to the ﬁrst mount
Intromission latency (IL): time from the introduction of the
female up to the ﬁrst intromission by the male
Ejaculation latency (EL): time from the ﬁrst intromission to
the ejaculation
Mount frequency (MF): number of mount in a sexual cycle
before ejaculation
intromission frequency (IF) : number of intromission in a
sexual cycle before ejaculation
Post-ejaculatory interval (PEI) : time from end of ﬁrst ejac-
ulation to start of next intromission
Determination of Smooth Muscle : Collagen Level
At the end of sexual behavior study, male rats were anes-
thetized (Ketamine 60 mg/kg, i.p.; Xylazine 10 mg/kg, i.p.),
penectomy was performed, and rats were sacriﬁced by cervical
dislocation. The shaft of penile tissue was dipped in 7% formalin
saline for 24 hours and then transferred to 70% ethanol until the
tissues were further processed. Masson’s trichrome staining was
performed to evaluate effect of treatment on smooth muscle:
collagen ratio of penile tissue as per published literature.19
Isolated Rat Corpus Cavernosum Study
Effect of phloroglucinol and sildenaﬁl was studied on isolated
corpus cavernosum collected from anesthetized normal and diabetic
rat (32 days after induction of diabetes) penile tissues.21 Brieﬂy,
CCSMs of dimension 3  3  15 mm were mounted in a four-
channel organ bath containing modiﬁed KrebseHenseleit salt so-
lution (composition [mM]: 118 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2
MgSO4, 1.5 CaCl2, 25 NaHCO3, 11 glucose) maintained at 37C.
CCSMs were stretched up to 500 mg tension and washed four
times within 1 hour of stabilzation period. The tissues were con-
tracted with 3 mM of phenylephrine and then different concen-
trations of phrologlucinol and sildenaﬁl were added separately to the
organ bath in the interval of 5 minutes each.
Effect of Phloroglucinol and Sildenaﬁl on Formation
of AGEs In Vitro
Effect of phloroglucinol and sildenaﬁl on advanced glycation end
product (AGE) was estimated using bovine serum albumin (BSA)-
glucose assay.16 Brieﬂy, different concentrations of phloroglucinol,
sildenaﬁl, and aminoguanidine (reference standard) solution con-
taining preservative sodium azide (0.02%) were incubated with
ﬁnal concentrations of BSA (2 mg/mL), glucose (40 mM) at 37C.
Positive control reaction without inhibitor was also set up.
All the solutions were stored in capped bottles in dark for 15
days. Fluorescence intensity of each solution was measured at% scavenging ¼ ½Absorbance of control Absorbance of test sampexcitation wavelength of 370 nm and emission wavelength of
440 nm.
DPPH Free Radical and NO Scavenging Assay
DPPH free radical and NO scavenging assay are commonly
employed to evaluate antioxidant potential of natural and syn-
thetic products. Assays were performed as described elsewhere.
Methanol was used as blank, and ascorbic acid was used as
standard antioxidant. All the readings were taken in triplicate,
that is, n ¼ 3 and absorbance was measured using Shimadzu
(UV-1601, Kyoto, Japan) UV-visible spectrophotometer. The
IC50 value for each test compound as well as standard prepara-
tion was calculated using the following formula.17
For DPPH scavenging assay, to 150 mL DPPH solution
(4.3 mg in 3.3 mL), 3 mL of methanol was added and absor-
bance was measured at 517 nm (control reading) after 15 minutes.
Similarly, for determining DPPH scavenging capacity of phlor-
oglucinol, to 3 mL solution of phloroglucinol in methanol,
150 mL of DPPH solution was added, and absorbance was
measured after 15 minutes at 517 nm.
For NO scavenging assay, different concentrations of phlor-
oglucinol were taken in separate test tubes, and the volume was
made up to 150 mL with methanol. Two milliliters of 10 mM
sodium nitroprusside in phosphate buffer saline was added to
each tube, and solutions were incubated for 2.5 h at 27C fol-
lowed by addition of 5 mL of Griess reagent. Absorbance was
measured at 546 nm.
Cytochrome P450 3A4 Study
Enzyme activity was studied as per available literature with
slight modiﬁcation.22,23 Brieﬂy, human CYP3A4 enzyme
(5 pmol/mL) suspended in 100 mM potassium phosphate buffer
(pH 7.4) containing magnesium chloride (35 mM) and ethyl-
enediamine tetracacetic acid (10 mM), was incubated with BFC
(10 mM). Reaction was started with addition of nicotinamide
adenine dinucleotide phosphatase (NADPH) regenerating
system containing 5 mM glucose-6-phosphate, 1 mM NADPþ,
and 1 unit/mL of glucose-6-phosphate dehydrogenase. Forma-
tion of HFC was recorded in kinetic mode (excitation 410 nm/
emission 510 nm) for 30 minutes.
STATISTICS
One-way analysis of variance followed by Tukey’s multiple
comparison test was employed to evaluate statistical signiﬁcance.
Values are presented as mean ± standard deviation or standard
error of mean. Statistical calculation was performed using
GraphPad Prism version 5 (GraphPad software company, La
Jolla, CA, USA). A P value < .05 was considered as statistically
signiﬁcant.le=Absorbance of control  100
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Figure 1. Effect of treatment on serum glucose level of diabetic
rats. Administration of streptozotocin increased serum glucose
level in rats signiﬁcantly in comparison with normal rats not
exposed to streptozotocin (***P < .001). Phloroglucinol (PG)
decreased serum glucose level signiﬁcantly (#P < .05 vs diabetic
rats treated with vehicle) while sildenaﬁl had no effect on glycemia.
Oneeway analysis of variance followed by Tukey multiple com-
parison test was used for calculating statistical signiﬁcance. Values
are represented as mean ± standard deviation of 6 observations.
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Effect of Treatment on Diabetes
Serum glucose levels in STZ diabetic rats increased
signiﬁcantly in comparison with normal rats (P < .001). A
slight but signiﬁcant decrease in serum glucose levels was
observed in diabetic rats treated with phloroglucinol in
comparison with diabetic rats treated with vehicle (P < .05).
Sildenaﬁl had no effect on serum glucose level of diabetic rats
(Figure 1).Effect of Treatment on Sexual Function
Sexual function of all rats in different groups on day 0 was
similar, but signiﬁcant changes were observed 28 days after
treatment. Sexual function of type 1 diabetic rats decreased
signiﬁcantly (P < .05) in comparison with normal rats. Phlor-
oglucinol and sildenaﬁl increased sexual function in diabetic rats,
but effect was statistically signiﬁcant only for sildenaﬁl. Co-
treatment of phloroglucinol and sildenaﬁl preserved the sexual
function in diabetic rats, and the effect was better when sildenaﬁl
was used alone (Table 1).Effect of Treatment on Smooth Muscle : Collagen
Level
Smooth muscle:collagen level decreased in diabetic rat penile
tissue in comparison with normal rats. Effect of treatment on
smooth muscle:collagen ratio was in order: sildenaﬁl þ phlor-
oglucinol > phloroglucinol > sildenaﬁl. Co-treatment improved
smooth muscle:collagen level in diabetic penile tissue compared
with water (Figure 2).Sex Med 2016;4:e106ee114Effect of Phloroglucinol and Sildenaﬁl on Isolated
Rat Corpus Cavernosum
Sildenaﬁl relaxed isolated rat CCSMs signiﬁcantly. Relaxation
effect of sildenaﬁl on isolated diabetic rat penile tissue was lesser
than the effect that was seen with normal rat isolated CCSMs.
Phloroglucinol did not signiﬁcantly relax isolated CCSM from
normal and diabetic rat (Table 2).Effect of Phloroglucinol on Formation of AGEs
In vitro, AGE inhibition potential of phloroglucinol was
better than aminoguanidine with IC50 48.38 ± 1.02 and
322.4 ± 0.98 mg/mL, respectively (Figure 3).DPPH Free Radical and NO Scavenging Assay
Phloroglucinol was very effective in scavenging DPPH free
radicals with an IC50 of 4.48 ± 0.54 mg/mL. Ascorbic acid was
better antioxidant than phloroglucinol in term of scavenging
DPPH with IC50 3.07 ± 0.76 mg/mL (Figure 4).
Ascorbic acid was efﬁcient in scavenging NO free radical with
IC50 13.92 ± 1.62 mg/mL, but phloroglucinol was not effective
in scavenging NO free radicals with an IC50 of 377.51 ± 1.31
mg/mL. (Figure 5).CYP3A4 Inhibition Assay
Ketoconazole, used as positive control, inhibited 90% of
CYP3A4 activity at a concentration of 10 nM, whereas IC50 of
phloroglucinol was found to be 108 ± 10 nM. IC50 of ketoco-
nazole, a standard human CYP3A4 inhibitor, was 1.8 ± 0.1 nM.DISCUSSION
This study proved usefulness of antioxidant therapy along with
standard erectogenic agent in the management of diabetes-induced
sexual dysfunction. Phloroglucinol decreased serum glucose level
signiﬁcantly (Table 1). Administration of both phloroglucinol and
sildenaﬁl prevented decrease in smooth muscle : collagen level
thereby preserving sexual function (Figure 2, Table 1). Phlor-
oglucinol inhibited AGEs formation in vitro suggesting its impor-
tance in minimizing AGEs-mediated sexual dysfunction (Figure 3,
Table 1). Antioxidant property of phloroglucinol and its ability to
inhibit CYP3A4 might be at least in part be responsible for
increasing efﬁcacy of sildenaﬁl (Figures 4 and 5, Table 1). Phlor-
oglucinol as such may not be useful in increasing sexual function in
normal animals because it did not relax isolated CCSM (Table 2).
However, the inhibition of CYP3A4 represents a bottleneck in the
clinical use of phloroglucinol and further studies are required.
Diabetes is associated with increased risk of sexual dysfunc-
tion.4,7,8,11,24,25 Increased AGEs, elevated levels of free radicals,
impaired NO synthesis, decrease in smooth muscle : collagen
ratio, impaired NO synthesis and availability, increased endo-
thelin B receptor binding sites, and upregulated RhoA/
Rho-kinase pathway have been proposed to facilitate diabetes-
induced ED.24e26 Controlling serum glucose level is a primary
Table 1. Phloroglucinol and sildenaﬁl increases sexual function of diabetic rats
Sexual behavior parameters
(unit)
Normal rat
(n ¼ 6)
Diabetic rats
Water (n ¼ 5)
Phloroglucinol
(n ¼ 5)
Sildenaﬁl
(n ¼ 5)
Phloroglucinol þ Sildenaﬁl
(n ¼ 6)
ML (second) 28.7 ± 3.8 56.8 ± 4.4$ 42.0 ± 4.0* 33.8 ± 5.0** 27.8 ± 3.5**
IL (second) 41.8 ± 3.9 80.8 ± 6.9$ 56.0 ± 5.2* 48.4 ± 4.7** 40.5 ± 4.5**
EL (second) 400.8 ± 26.3 270.4 ± 14.1$ 321.4 ± 27.6* 383.0 ± 16.1** 410.5 ± 15.8**
MF (number) 14.0 ± 2.1 5.4 ± 0.7$ 9.4 ± 1.2* 12.6 ± 1.1** 14.2 ± 1.4**
IF (number) 9.8 ± 0.6 3.4 ± 0.6$ 6.4 ± 0.9* 8.6 ± 0.8** 10.0 ± 1.0**
PEI (second) 345.3 ± 16.9 718.6 ± 23.2$ 553.2 ± 24.6* 499.8 ± 33.1** 402.7 ± 12.5**
Diabetes decreased sexual function of rats signiﬁcantly ($P < .05). ML, IL, and PEI of rats with diabetes increased signiﬁcantly ($P < .05), whereas MF, IF,
and EL of diabetic rats decreased signiﬁcantly ($P < .05) in comparison with normal healthy rats inferring the development of sexual dysfunction in diabetic
rats.11,20 Phloroglucinol, sildenaﬁl, and Phloroglucinol þ sildenaﬁl increased sexual function of diabetic rats signiﬁcantly (*P < .05, **P < .01). One rat each
from water, phloroglucinol and sildenaﬁletreated diabetic group did not respond to treatment and were excluded from statistical data calculation. Data are
presented as mean ± standard error of mean. One-way ANOVA followed by Tukey’s multiple comparison test was used for statistical analysis.
e110 Goswami et alfactor in the management of diabetes-induced erectile
dysfunction (DIED).24 Phloroglucinol increased efﬁcacy of
sildenaﬁl by decreasing glucose level though it did not show any
effect on CCSM.Figure 2. Effect of treatment on smooth muscle : collagen level in ra
and imaged through light microscopy (40). Smooth muscle is stained
using software ImageJ of NIH (Bethesda, MD, USA). Smooth muscle :
in comparison with normal rats. Phloroglucinol (PG) þ sildenaﬁl treatm
level in penile tissue of diabetic rats in comparison with diabetic rat t
mean of four observations. One way ANOVA followed by Tukeys mulSmooth muscles of corpus cavernosum play important role in
penile erection. Relaxation of CCSM along with penile artery
allows accumulation of blood in penis and stoppage of venous
outﬂow ensures erection.26 Arginine/NO/cyclic guanosinet penile tissue (A) CCSM stained with Masson’s trichrome staining
pink, whereas collagen is stained as blue. (B) Images were analyzed
collagen level had decreased ($$P < .01) in diabetic rat penile tissue
ent was effective (**P < .01) in improving smooth muscle : collagen
reated with only water. Value represents mean ± standard error of
tiple comparison test was used for statistical analysis.
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Table 2. Sildenaﬁl Relaxes Corpus Cavernosum of Normal and Diabetic Rats
Concentration of phloroglucinol
and sildenaﬁl (mg/mL)
Normal rat (% relaxation) Diabetic rat (% relaxation)
Water Phloroglucinol Sildenaﬁl Water Phloroglucinol Sildenaﬁl
0.01 0.6 ± 0.2 0.8 ± 0.3 9.5 ± 1.7* 0.5 ± 0.1$ 0.4 ± 0.1 3.5 ± 0.9#
0.1 1.2 ± 0.3 2.0 ± 0.4 19.3 ± 3.2* 1.0 ± 0.2$ 1.0 ± 0.2 11.3 ± 2.6#
1 2.7 ± 0.5 6.2 ± 1.4 39.5 ± 5.8* 1.6 ± 0.2$ 2.0 ± 0.3 27.8 ± 5.2#
10 4.7 ± 0.5 13.6 ± 1.9 85.7 ± 3.5* 2.8 ± 1.1$ 5.3 ± 1.0 65.8 ± 9.8#
Table 2 illustrates effect of phloroglucinol and sildenaﬁl on percent relaxation of phenylephrine precontracted isolated CCSMs of normal and diabetic rat in
comparison with water. Sildenaﬁl signiﬁcantly (*P < .05 vs water) relaxed CCSM of normal rat while phloroglucinol could not relax CCSM signiﬁcantly.
Relaxation effect of CCSMs of diabetic rat decreased signiﬁcantly ($P < .05) in comparison with normal rats and sildenaﬁl could signiﬁcantly relax (#P < .05
vs water) CCSM of diabetic rat.11,19,21 n ¼ 6. Values are presented as mean ± standard error of mean.
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RhoA/ROCK pathway contracts the smooth muscles in the
penile tissue. A balance between relaxation and contraction of
CCSM regulates penile erection.24e26 Oxidative stress-induced
decrease in smooth muscle:collagen ratio was reported in
CCSM of streptozotocin-induced diabetic rat.27 In our study,
smooth muscle:collagen ratio decreased signiﬁcantly in penile
tissue of diabetic rats when compared with normal healthy
rats. Smooth muscle:collagen ratio level in the penile tissue of
diabetic rats treated with phloroglucinol þ sildenaﬁl was better
in comparison with control diabetic rats (Figure 2). In addition
to this, effect of phloroglucinol in decreasing formation of AGE
and antioxidant property might have improved efﬁcacy of
sildenaﬁl.
Mechanism of AGEs-induced sexual dysfunction in diabetes is
extensively discussed elsewhere.15 Brieﬂy, AGEs are generated by
glycation of proteins. In diabetes, levels of AGEs are elevated due
to increased blood glucose levels. AGEs-induced ED results from
vascular wall thickening and decreased elasticity arising due to
formation of covalent bond with collagen. Increase in levels of
AGEs in serum is reported to increase the expression and activity
of NADPH oxidase, which in turn increases oxidative stress in
CCSM by generation of reactive free radicals. AGEs decreasesFigure 3. Phloroglucinol inhibits formation of advanced glycation
end products (AGEs) in vitro. Aminoguanidine known to inhibit
AGEs is less effective than phloroglucinol. Data represent mean ±
standard error of mean of three observations.
Sex Med 2016;4:e106ee114expression of antioxidant enzyme Mn-superoxide dismutase,
thereby decreasing antioxidant defense system. In addition,
AGEs decrease endothelial nitric oxide synthase (eNOS) mRNA
expression and uncouples eNOS, which decrease production of
NO that relaxes CCSM by elevating production of cGMP. AGEs
regulate smooth muscle contraction through Rho as Y27632, a
Rho kinase inhibitor inhibits AGE-BSA-induced cell contrac-
tion.28 Antibody to AGE receptor inhibits AGEeBSA-induced
cell contraction, and breakdown of preformed AGEs reverses ED
in STZ-induced diabetic rats.29 We observed that in our study,
phloroglucinol was more effective than aminoguanidine in
decreasing AGE formation in vitro. Diabetes-induced oxidative
stress and decrease in levels of antioxidant in penile tissue pro-
mote collagen deposition and ﬁbrosis of penile tissue resulting in
ED. Phloroglucinol exhibited potent antioxidant activity in vitro
and efﬁcacy of phloroglucinol to decrease DIED could be partly
attributed to this antioxidant activity. Advantage of phlor-
oglucinol over other antioxidants such as ellagic acid11 and
vitamin E7 in DIED is due to its effect on reducing glycemia.
Though phloroglucinol increases efﬁciency of sildenaﬁl, it is least
effective than sildenaﬁl in management of DIED.
Apart from PDE5 inhibition, efﬁcacy of sildenaﬁl in DIED
might be through different mechanisms due to its effect on
testosterone, inﬂammation, oxidative stress, RhoA/ROCK
signaling etc. DIED is associated with hypogonadism, decrease in
the mRNA level of neural nitric oxide synthase (nNOS) and
PDE5, and upregulation of RhoA/ROCK pathway in penile
tissue. Testosterone supplementation increases the erectile
response in diabetic rats along with increase in level of nNOS
and PDE5 in comparison with diabetic control rats in addition
to normalization of RhoA/ROCK pathway upregulation.30e32
Sildenaﬁl also increases erectile function and serum testos-
terone level signiﬁcantly in men with ED associated with low
testosterone level.33 Limitation of this study is lack of data on
level of testosterone after sildenaﬁl treatment. PDE5 inhibitors
such as tadalaﬁl and vardenaﬁl exert anti-inﬂammatory effect in
human benign prostrate hyperplasia.34 Sildenaﬁl decreases
inﬂammation and oxidative stress in pelvic ganglia neurons
associated with bilateral cavernosal nerve damage in rats.
Figure 4. Percent reduction of DPPH by phloroglucinol and
standard antioxidant ascorbic acid. Value represents mean ±
standard error of mean of three observations.
e112 Goswami et alSildenaﬁl also restores endothelial NOS and PDE5 in addition to
its ability to control oxidative/nitrosative stress in mouse
penis.35,36 Therefore, anti-inﬂammatory and antioxidant effect
of PDE5 inhibitors such as sildenaﬁl might help in mitigating
DIED in addition to their effect on PDE5. Administration of
tadalaﬁl, a PDE5 reduces visceral fat weight, RhoA/ROCK
signaling and smooth muscle over activity in a rabbit model of
high fat diet-induced metabolic syndrome. Though sildenaﬁl
could not decrease glycemia in this study, it might have
improved sexual function in diabetic animals by suppressing
RhoA/ROCK signaling and smooth muscle over activity.37
Phloroglucinol inhibited CYP3A4, the enzyme that metabo-
lizes sildenaﬁl, therefore, co-treatment with sildenaﬁl may in-
crease the efﬁcacy of sildenaﬁl by increasing its concentration in
the blood. Potential of phloroglucinol to inhibit CYP3A4 might
increase level of sildenaﬁl in treated individuals when coad-
ministered thereby increasing its bioavailability, efﬁcacy, and
perhaps toxicity. A similar inhibition potential of phloroglucinolFigure 5. Percent reduction of NO by phloroglucinol and standard
antioxidant ascorbic acid in vitro. Value presents mean ± standard
error of mean. Assay was performed in triplicate.on rat CYP3A1, ortholog to human CYP3A4 is expected. This
study also shed a light on potential herbedrug interaction that
could come in picture when an herbal product containing
phloroglucinol is co-administered with sildenaﬁl. Though PDE5
inhibitor such as sildenaﬁl is ﬁrst line of drug for management of
DIED, adverse events are reported. Phloroglucinol may increase
adverse effect of sildenaﬁl such as headache, ﬂushing, abnormal
vision, nasal congestion, myalgia, back pain, cardiovascular dis-
order, etc.38 Further studies are required to shed more light on
the potential drug interactions of phloroglucinol with other drugs
metabolized by CYP3A4.
CONCLUSION
Preventative treatment of phloroglucinol could be helpful to
manage diabetes-induced ED. The efﬁcacy of phloroglucinol
could be due to its ability to decrease serum glucose level and
formation of AGEs and its antioxidant property. Phloroglucinol
coadministration with sildenaﬁl increases efﬁcacy of sildenaﬁl in
diabetic rats. Inhibition of CYP3A4 by phloroglucinol indicates a
potential drug interaction with drugs that are substrates for the
enzyme. We also propose that further studies are required to
ascertain the usefulness of phloroglucinol in the management of
diabetes-induced sexual dysfunction.ACKNOWLEDGMENTS
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